Medical biotechnology in the service of coronavirus vaccine discovery and production 2 2 No Abstract 105 106 Ahmad Shamabadi Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences Iran Shahin Akhondzadeh BiotechnologyCoronavirusCOVID-19SARS-CoV-2Vaccines 40472.pdf ####

The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds 2 2 Background: The cause of COVID-19 global pandemic is SARS-CoV-2. Given the outbreak of this disease, it is so important to find a treatment. One strategy to cope with COVID-19 is to use the active ingredients of medicinal plants. In this study, the effect of active substances was surveyed in inhibiting four important druggable targets, including S protein, 3CLpro, RdRp, and N protein. RdRp controls the replication of SARS-CoV-2 and is crucial for its life cycle. 3CLpro is the main protease of the virus and could be another therapeutic target. Moreover, N protein and S protein are responsible for SARS-CoV-2 assembly and attaching, respectively. Methods: The 3D structures of herbal active ingredients were prepared and docked with the mentioned SARS-CoV-2 proteins to obtain their affinity. Then, available antiviral drugs introduced in other investigations were docked using similar tools and compared with the results of this study. Finally, other properties of natural compounds were uncovered for drug designing. Results: The outcomes of the study revealed that Linarin, Amentoflavone, (-)-Catechin Gallate and Hypericin from Chrysanthemum morifolium, Hypericum perforatum, Humulus lupulus, and Hibiscus sabdariffa had the highest affinity for these basic proteins and in some cases, their affinity was much higher than antiviral medicines. Conclusion: In addition to having high affinity, these herb active ingredients have antioxidant, vasoprotective, anticarcinogenic, and antiviral properties. Therefore, they can be used as extremely safe therapeutic compounds in drug design studies to control COVID-19. 107 115 Samira Mahmoudi Department of Microbial Biotechnology, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University Department of Microbial Biotechnology, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University Iran Negar Balmeh Department of Cell and Molecular Biology, Faculty of Biology, Nour Danesh Institution of Higher Education Department of Cell and Molecular Biology, Faculty of Biology, Nour Danesh Institution of Higher Education Iran Niloofar Mohammadi Department of Sciences and Agricultural Engineering, School of Agricultural Sciences, Pir Bakran Branch, Payame Noor University, Department of Sciences and Agricultural Engineering, School of Agricultural Sciences, Pir Bakran Branch, Payame Noor University, Iran Tahereh Sadeghian-Rizi COVID-19Drug designMedicinalPlantsSARS-CoV-2 40462.pdf Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-3. ##Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579(7798):265-9. ##Coronaviridae Study Group of the International Committee on Taxonomy of Viruses: Gorbalenya AA, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;2020:536-44. ##Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol 2020;42(1):3-11. ##Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20. ##De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14(8):523-34. ##Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics 2020;10(17):7821-35. ##Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group; 2020.##Lisi L, Lacal PM, Barbaccia ML, Graziani G. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochem Pharmacol 2020;114169. ##Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181(2):281-92. ##Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3):226-36. ##Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 2017;21(2):131-43. ##Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 2020;10(16):7448-64. ##Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-80. ##Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11(1):1620. ##Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92(4):418-23. ##Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate immunity. Front Microbiol 2014;5:296. ##Peng H, Yang L, Wang L, Li J, Huang J, Lu Z, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 2006;351(2):466-75. ##Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12(3):254. ##Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300(5626):1763-7.##Needle D, Lountos GT, Waugh DS. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr Sect D Biol Crystallogr 2015;71(5):1102-11. ##ul Qamar MT, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020;10(4):313-9. ##Smertina E, Urakova N, Strive T, Frese M. Calicivirus RNA-dependent RNA polymerases: evolution, structure, protein dynamics and function. Front Microbiol 2019;10:1280.##Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV. Chembiochem 2020; 21(5):730-8. ##Lung J, Lin Y, Yang Y, Chou Y, Shu L, Cheng Y, et al. The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase. J Med Virol 2020;92(6):693-7.##Jia H, Gong P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Front Microbiol 2019;10:1945. ##Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells 2020;9(5):1267. ##Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;104762. ##Chandel V, Sharma PP, Raj S, Choudhari R, Rathi B, Kumar D. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2. J Biomol Struct Dyn 2020;1-14. ##Alexpandi R, De Mesquita JF, Pandian SK, Ravi AV. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front Microbiol 2020;11:1796. ##Mosquera-Yuqui F, Lopez-Guerra N, Moncayo-Palacio EA. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. J Biomol Struct Dyn 2020;1-14. ##Lalani S, Poh CL. Flavonoids as antiviral agents for Enterovirus A71 (EV-A71). Viruses 2020;12(2):184. ##Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2020;35(1):145-51. ##Hulo C, De Castro E, Masson P, Bougueleret L, Bairoch A, Xenarios I, et al. ViralZone: a knowledge resource to understand virus diversity. Nucleic Acids Res 2011;39(Database issue):D576-82. ##Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2005;33(Database issue):D501-4. ##Haasnoot J, Berkhout B. RNAi and cellular miRNAs in infections by mammalian viruses. In: Antiviral RNAi. Springer; 2011. p. 23-41.##Peele KA, Chandrasai P, Srihansa T, Krupanidhi S, Sai AV, Babu DJ, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked 2020;100345. ##Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 2010;84(24):12658-64. ##Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011;85(2):873-82. ##Filimonov DA, Lagunin AA, Gloriozova TA, Rudik A V, Druzhilovskii DS, Pogodin P V, et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd 2014;50(3):444-57. ##Maunz A, Gütlein M, Rautenberg M, Vorgrimmler D, Gebele D, Helma C. Lazar: a modular predictive toxicology framework. Front Pharmacol 2013;4:38.##Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020;20(7):816-26. ##Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396(10249):479-88. ##Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci 2020;16(10):1678-85. ##Zheng L, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem 2020;112687. ##Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020;157:104833. ##Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 2004;43(17):4906-12.##Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. J Biomol Struct Dyn 2020;1-9. ##Balmeh N, Mahmoudi S, Mohammadi N, Karabedianhajiabadi A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inform Med Unlocked 2020;100407. ##Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. BioRxiv. 2020;##Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. BioRxiv. 2020; ##Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, et al. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. J Biomol Struct Dyn 2020;1-14. ##Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn 2020;2607-16. ##Hendaus MA. Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary. J Biomol Struct Dyn 2020;1-6. ##Food and Drug Administration. Remdesivir EUA Letter of Authorization - FDA [Internet]. Vol. 364 KB. 2020. p. 6. Available from: https://www.fda.gov/media/137564/download##Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Comput Biol Med 2021;133:104359. ##

The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance as well as Migration in Colon Cancer 2 2 Background: Nuclear factor-erythroid 2-related factor 2 (Nrf2) plays a key role in promoting chemoresistance in various cancers. PD-L1 is one of the downstream targets of the Nrf2 signaling pathway. This molecule has some beneficial impacts on tumors growth by inhibition of the immune system. This study aimed to investigate the potential role of the Nrf2-PD-L1 axis in the promotion of oxaliplatin resistance in colon cancer cells. Methods: We examined Nrf2, PD- L1, and CD80 expression in the tumor and margin tissue samples from CRC patients. After that role of the Nrf2-PD-L1 axis in promotion of Oxaliplatin resistance was investigated. Results: Our data revealed that Nrf2 and PD-L1 mRNA expressions were markedly higher in tumor tissues compared to margin tissues. The PD-L1 mRNA expression level was also increased in the resistant cells. However, Nrf2 expression was decreased in SW480/Res cells and increased in LS174T/Res cells. The inhibition of Nrf2 through siRNA treatment in SW480/Res and LS174T/Res cells has decreased the IC50 values of oxaliplatin. Inhibition of the Nrf2 has significantly increased the oxaliplatin-induced apoptosis, and reduced the migration in SW480/Res cells. Conclusion: It is suggested that effective inhibition of Nrf2-PD-L1 signaling pathways can be considered as a novel approach to improve oxaliplatin efficacy in colon cancer patients. 116 122 Zahra Payandeh Immunology Research Center, Tabriz University of Medical Sciences Immunology Research Center, Tabriz University of Medical Sciences Iran Abbas Pirpour Tazehkand Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran Iran Behzad Mansoori Immunology Research Center, Tabriz University of Medical SciencesDepartment of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark Drug Applied Research Center, Tabriz University of Medical Sciences Immunology Research Center, Tabriz University of Medical SciencesDepartment of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark Drug Applied Research Center, Tabriz University of Medical Sciences IranDenmarkIran Vahid Khaze Immunology Research Center, Tabriz University of Medical Sciences Immunology Research Center, Tabriz University of Medical Sciences Iran Milad Asadi Immunology Research Center, Tabriz University of Medical Sciences Immunology Research Center, Tabriz University of Medical Sciences Iran Behzad Baradaran Nasser Samadi Colonic neoplasmsHumansNF-E2-Related Factor 2OxaliplatinSignal transduction 40463.pdf Bendardaf R, El-Serafi A, Syrjänend K, Collan Y, Pyrhönen S. The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients. Libyan J Med 2017;12(1):1290741.##Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, et al. Zhao, MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep 2017;38(3):1383-92. ##Motohashi H, Yamamoto M. Nrf2–Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10(11):549-57.##Kahroba H, Ramezani B, Maadi H, Sadeghi MR, Jaberie H, Ramezani F. The role of Nrf2 in Neural stem/Progenitors cells: from maintaining stemness and self-renewal to promoting differentiation capability and facilitating therapeutic application in neurodegenerative disease. Ageing Res Rev 2021;65:101211.##Payandeh Z, Pirpour Tazehkand A, Barati G, Pouremamali F, Kahroba H, Baradaran B, et al. Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance. Biochimie 2020;179:32-45.##Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A, Morel F. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer 2009;45(12):2219-27.##Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011;71(5):1999-2009.##Zhao M, Xu H, Zhang B, Hong B, Yan W, Zhang J. Impact of nuclear factor erythroid-derived 2–like 2 and p62/sequestosome expression on prognosis of patients with gliomas. Hum Pathol 2015;46(6):843-9.##Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887-95.##Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.##Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier M,et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.##Kaufman Hl, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17(10):1374-85.##Romero D. Immunotherapy: Atezolizumab becomes POPLAR. Nat Rev Clin Oncol 2016;13(5):266.##Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene 2018;37(36):4941-4954.##Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001;60(4):1343-53.##Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice. J Clin Invest 2004;114(9):1248-59.##Hudson AL, Weir C, Moon E, Harvie R, Klebe S, Clarke SJ, et al. Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep 2014;4:6152.##McDermott M, Eustace A, Busschots S, Breen L, Clynes M, O'Donovan N, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol 2014;4:40.##Tazehkand AP, Akbarzadeh M, Velaie K, Sadeghi MR, Samadi N. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells. Biomed Pharmacother 2018;103:755-66.##Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N. Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep 2016;43(2):99-105.##Akbarzadeh M, Nouri M, Banekohal MV, Cheraghi O, Tajalli H, Movassaghpour A, et al. Effects of combination of melatonin and laser irradiation on ovarian cancer cells and endothelial lineage viability. Lasers Med Sci 2016;31(8):1565-72.##Armat M, Bakhshaiesh TO, Sabzichi M, Shanehbandi D, Sharifi S, Molavi O, et al. The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci 2016;16(1):28-34.##Gandomani HS, Aghajani M, Mohammadian-Hafshejani A, Tarazoj AA, Pouyesh V, Salehiniya H. Colorectal cancer in the world: incidence, mortality and risk factors., Biomedical Research and Therapy 2017;4(10):1656-75.##Sadeghi MR, Jeddi F, Soozangar N, Somi MH, Shirmohamadi M, Khaze V, et al. Nrf2/P–glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer Biomed Pharmacother 2018;104:458-464.##Wang J, Zhang M, Zhang L, Cai H, Zhou S, Zhang J, et al. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J Surg Res 2010 ;164(1):e99-105.##Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev 2014;15(13):5311-6.##Duong HQ, You KS, Oh S, Kwak SJ, Seong YS. Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1 and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants (Basel) 2017;6(3):52.##Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, et al. Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells. Drug Metab Dispos 2018;46(1):2-10.##Wang J, Wang H, Sun K, Wang X, Pan H, Zhu J, et al. Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway. Drug Des Devel Ther 2018;12:721-733.##Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, et al. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med 2013;41(1):177-96.##

Designing a Strategy for pH Control to Improve CHO Cell Productivity in Bioreactor 2 2 Background: Drastic pH drop is a common consequence of scaling up a mammalian cell culture process, where it may affect the final performance of cell culture. Although CO2 sparging and base addition are used as common approaches for pH control, these strategies are not necessarily successful in large scale bioreactors due to their effect on osmolality and cell viability. Accordingly, a series of experiments were conducted using an IgG1 producing Chinese Hamster Ovary (CHO-S) cell culture in 30 L bioreactor to assess the efficiency of an alternative strategy in controlling culture pH. Methods: Factors inducing partial pressure of CO2 and lactate accumulation (as the main factors altering culture pH) were assessed by Plackett-Burman design to identify the significant ones. As culture pH directly influences process productivity, protein titer was measured as the response variable. Subsequently, Central Composite Design (CCD) was employed to obtain a model for product titer prediction as a function of individual and interaction effects of significant variables. Results: The results indicated that the major factor affecting pH is non-efficient CO2 removal. CO2 accumulation was found to be affected by an interaction between agitation speed and overlay air flow rate. Accordingly, after increasing the agitation speed and headspace aeration, the culture pH was successfully maintained in the range of 6.95-7.1, resulting in 51% increase in final product titer. Similar results were obtained during 250 L scale bioreactor culture, indicating the scalability of the approach. Conclusion: The obtained results showed that pH fluctuations could be effectively controlled by optimizing CO2 stripping. 123 130 Zohreh Ahleboot Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Mahdi Khorshidtalab Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Paria Motahari Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Rasoul Mahboudi Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Razieh Arjmand Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Aram Mokarizadeh Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Biopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Sciences Iran Shayan Maleknia Carbon dioxideCell survivalHydrogen-ion concentrationImmunoglobulin G (IgG)Lactic acid 40464.pdf Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs 2014;7(1):9-14.##Zhang J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012;30(5):1158-70.##Bandaranayake AD, Almo SC. Recent advances in mammalian protein production. FEBS lett 2014;588(2):253-60.##Gowtham YK. Understanding the Transcriptional Landscape of Chinese Hamster Ovary (CHO) Cell Lines Using Next-Generation Sequencing Technology, RNAseq, under Industrially Relevant Conditions. Clemson University; PhD thesis, 2016.##Brunner M, Fricke J, Kroll P, Herwig C. Investigation of the interactions of critical scale-up parameters (pH, pO2 and pCO2) on CHO batch performance and critical quality attributes. Bioprocess Biosyst Eng 2017;40(2):251-63.##Kim HS, Lee GM. Differences in optimal pH and temperature for cell growth and antibody production between two Chinese hamster ovary clones derived from the same parental clone. J Microbiol Biotechnol 2007;17(5):712-20.##Finter NB, Garland AJ, Telling RC. Large-Scale Mammalian Cell Culture Technology: 1st ed. New York: Taylor & Francis; 1990.##Hoshan L, Jiang R, Moroney J, Bui A, Zhang X, Hang TC, et al. Effective bioreactor pH control using only sparging gases. Biotechnol Prog 2019;35(1):e2743.##Satake H, Saito A, Sakata T. Elucidation of interfacial pH behaviour at the cell/substrate nanogap for in situ monitoring of cellular respiration. Nanoscale 2018;10(21):10130-6.##Li J, Wong CL, Vijayasankaran N, Hudson T, Amanullah A. Feeding lactate for CHO cell culture processes: impact on culture metabolism and performance. Biotechnol Bioengin 2012;109(5):1173-86.##Konakovsky V, Clemens C, Müller MM, Bechmann J, Berger M, Schlatter S, et al. Metabolic control in mammalian fed-batch cell cultures for reduced lactic acid accumulation and improved process robustness. Bioengin (Basel) 2016;3(1):5.##Bowers J. Sparger and Surface Gas Transfer for Cell Culture Bioreactors. AIChE Annual meeting. 2008.##Mostafa SS, Gu X. Strategies for improved dCO2 removal in large-scale fed-batch cultures. Biotechnol prog 2003;19(1):45-51.##Jacob B, Von Dassow P, Salisbury J, Navarro J, Vargas C. Impact of low pH/high pCO2 on the physiological response and fatty acid content in diatom Skeletonema pseudocostatum. J Mar Biol 2016;97(2):1-9.##Irfan K. Carbon dioxide control in bioreactors and the application of principal component analysis to cell culture process data. Newcastle University; PhD thesis, 2017.##Xu S, Jiang R, Mueller R, Hoesli N, Kretz T, Bowers J, et al. Probing lactate metabolism variations in large-scale bioreactors. Biotechnol Prog 2018;34(3):756-66.##Buchsteiner M, Quek LE, Gray P, Nielsen LK. Improving culture performance and antibody production in CHO cell culture processes by reducing the Warburg effect. Biotechnol Bioengin 2018;115(9):2315-27.##Lee KM, Gilmore DF. Statistical experimental design for bioprocess modeling and optimization analysis. Appl Biochem Biotechnol 2006;135(2):101-16.##Ji Y. Model based process design for bioprocess optimisation: case studies on precipitation with its applications in antibody purification: University College London; PhD thesis, 2012.##Xu S, Chen H. High-density mammalian cell cultures in stirred-tank bioreactor without external pH control. J Biotechnol 2016;231:149-59.##Mandenius CF, Brundin A. Bioprocess optimization using design-of-experiments methodology. Biotechnol Prog 2008;24(6):1191-203.##Flickinger MC, Delvigne F, Lecomte J. Foam formation and control in bioreactors. Encyclopedia of Industrial Biotechnology. 1st ed. New York: Wiley online library; 2010.##Zagari F, Jordan M, Stettler M, Broly H, Wurm FM. Lactate metabolism shift in CHO cell culture: the role of mitochondrial oxidative activity. N Biotechnol 2013;30(2):238-45.##Restelli V, Wang MD, Huzel N, Ethier M, Perreault H, Butler M. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol Bioengin 2006;94(3):481-94.##Ozturk SS, Jorjani P, Taticek R, Lowe B, Shackleford S, Ladehoff-Guiles D. Kinetics of glucose metabolism and utilization of lactate in mammalian cell cultures. In: Carrondo MJT, et al. Animal Cell Technology. Netherlands: Kluwer Academic Publishers; 1997. p.355–360.##Lao MS, Toth D. Effects of ammonium and lactate on growth and metabolism of a recombinant Chinese hamster ovary cell culture. Biotechnol Prog 1997;13(5):688-91.##Zhou M, Crawford Y, Ng D, Tung J, Pynn AF, Meier A, et al. Decreasing lactate level and increasing antibody production in Chinese Hamster Ovary cells (CHO) by reducing the expression of lactate dehydrogenase and pyruvate dehydrogenase kinases. J Biotechnol 2011;153(1-2):27-34.##Osman JJ, Birch J, Varley J. The response of GS-NS0 myeloma cells to pH shifts and pH perturbations. Biotechnol Bioeng 2001;75(1):63-73.##Hu W, Berdugo C, Chalmers JJ. The potential of hydrodynamic damage to animal cells of industrial relevance: current understanding. Cytotechnol 2011;63(5):445-60.##Qi HN. Membrane and Micro-sparging Aerations in Long-term High-density Perfusion Cultures of Animal Cells: Oregon State University; PhD thesis, 2002.##Zhao LC, He Y, Deng X, Yang GL, Li W, Liang J, et al. Response surface modeling and optimization of accelerated solvent extraction of four lignans from fructus schisandrae. Molecules 2012;17(4):3618-29.##Chopda VR, Holzberg T, Ge X, Folio B, Wong L, Tolosa M, et al. Real-time dissolved carbon dioxide monitoring II: Surface aeration intensification for efficient CO(2) removal in shake flasks and mini-bioreactors leads to superior growth and recombinant protein yields. Biotechnol Bioengin 2020;117(4):992-8.##Shetty S. Effect of temperature and agitation rate variation on the growth of NS0 cell line in monoclonal antibody production. bioRxiv 2019;822601.##Xing Z, Lewis AM, Borys MC, Li ZJ. A carbon dioxide stripping model for mammalian cell culture in manufacturing scale bioreactors. Biotechnol Bioengin 2017;114(6):1184-94.##

Expression and Characterization of Two DNA Constructs Derived from HIV-1-vif in Escherichia coli and Mammalian Cells 2 2 Background: Acquired immunodeficiency syndrome (HIV/AIDS) is still a major global concern and no effective therapeutic vaccine has been produced to prevent the problem. Among HIV-1 proteins, vif as a basic cytoplasmic protein of HIV-1 is involved in late stages of viral generation and plays important role in HIV-1 virion replication. It also increases the stability of virion cores, which probably inhibits early degradation of viral entry. Therefore, it seems rational to apply this protein as a vaccine based on its impact on HIV-1 life cycle. This study aimed at cloning, expression and production of vif protein as an HIV-1 vaccine candidate. Methods: In this study, vif sequence was amplified from pLN4-3 plasmid including HIV-1 vif gene and then cloned in pET23a to generate the recombinant plasmids of pET23a/vif with hexahistidine tags. BL21 competent cells were transformed to obtain the protein of interest. Ni-NTA column was used to purify the protein of interest and western blotting confirmed vif protein using anti-His tag antibody. In order to express the gene of interest in eukaryotic cells, vif was sub-cloned into pEGFP plasmids and HEK 293-T cells were transfected. Flow cytometry was then applied to evaluate GFP expression. Results: vif protein was expressed in BL21)DE3) strain and identified as a23 kDa band in SDS-PAGE and confirmed by anti-His antibody in western blotting. The purified protein concentration was 173.3 μg/ml using Bradford assay. HEK-293T cells were successfully transfected by recombinant pEGFP plasmids and flow cytometry confirmed the cell transfection. Conclusion: vif protein can be expressed in mammalian cells and may be a proper protein subunit vaccine candidate against HIV-1. 131 135 Fatemeh Zamani Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of IranDepartment of Biology, Science and Research Branch, Islamic Azad University Department of Biology, Science and Research Branch, Islamic Azad University IranIran Azam Bolhassani Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of Iran Iran Sepideh Shahbazi Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of Iran Iran Ahmad Faghih Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of IranDepartment of Biology, Science and Research Branch, Islamic Azad University Department of Biology, Science and Research Branch, Islamic Azad University IranIran Seyed Mehdi Sadat HIV-1VaccinesVif protein 40465.pdf Global HIV & AIDS statistics [Internet]. 2019. Available from: aidsinfo.unaids.org.##Progress report on HIV, viral hepatitis and sexually transmitted infections 2019 [Internet]. Available from: https://www.who.int/hiv/strategy2016-2021/progress-report-2019/en/##Chibawara T, Mbuagbaw L, Kitenge M, Nyasulu P. Effects of antiretroviral therapy in HIV-positive adults on new HIV infections among young women: a systematic review protocol. Syst Rev 2019;8(1):68.##Larijani MS, Ramezani A, Sadat SM. Updated studies on development of HIV therapeutic vaccine. Curr HIV Res 2019;17(2):75-84.##Barry SM, Lora AJM, Novak RM. Trial, error, and breakthrough: A review of HIV vaccine development. J AIDS Clin Res 2014;5(11).##Bolhassani A, Kardani K, Vahabpour R, Habibzadeh N, Aghasadeghi MR, Sadaet SM, et al. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunol Lett 2015;168(2):366-73.##Larijani MS, Sadat SM, Bolhassani A, Pouriayevali MH, Bahramali G, Ramezani A. In silico design and immunologic evaluation of HIV-1 p24-Nef fusion protein to approach a therapeutic vaccine candidate. Curr HIV Res 2018;16(5):322-37.##Koff WC. A shot at AIDS. Curr Opin Biotechnol 2016;42:147-51.##McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012;13(5):423-7.##Larijani MS, Pouriayevali MH, Sadat SM, Ramezani A. Production of recombinant HIV-1 p24-Nef protein in two forms as potential candidate vaccines in three vehicles. Curr Drug Deliv 2020;17(5):387-95.##Seelamgari A, Maddukuri A, Berro R, de la Fuente C, Kehn K, Deng L, et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004;9:2388-413.##Freed EO. HIV-1 assembly, release and maturation. Nature Rev Microbiol 2015;13(8):484-96.##David M. Knipe PH. Fields Virology. 6th edition. USA: Lippincot Willaims & Wilkins; 2013. 2430 p.##Du J, Wu X, Long F, Wen J, Hao W, Chen R, et al. Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant. Viral Immunol 2013;26(1):68-74.##Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418(6898):646-50.##Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol 2014;88(5):2633-44.##Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009;73(2):211-32.##Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (New York, NY) 2003;300(5622):1112.##Sadat SM, Zabihollahi R, Aghasadeghi MR, Vahabpour R, Siadat SD, Memarnejadian A, et al. Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1. Curr HIV Res 2011;9(3):140-7.##Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003;12(3):591-601.##Doi N, Koma T, Adachi A, Nomaguchi M. Expression level of HIV-1 Vif can be fluctuated by natural nucleotide variations in the vif-coding and regulatory SA1D2prox sequences of the proviral genome. Front Microbiol 2019;10(2758).##Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76(9):4350-4.##Sambrook JF, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd ed., Vols 1,2 and 3. New York: Cold Spring Harbor Laboratory Press; 2001. 2100 p.##Mona Sadat L, Amitis R, Seyed Mehdi S. Updated studies on the development of HIV therapeutic vaccine. Curr HIV Res 2019;17(2):75-84.##Sadat Larijani M, Sadat SM, Bolhassani A, Ramezani A. A shot at dendritic cell-based vaccine strategy against HIV-1. J Med Microbiol Infect Dis (JoMMID) 2020;7(4):89-92.##Mona Sadat L, Seyed Mehdi S, Azam B, Pouriayevali MH, Bahramali G, Ramezani A. In silico design and immunologic evaluation of HIV-1 p24-Nef fusion protein to approach a therapeutic vaccine candidate. Current HIV Res 2018;16(5):322-37.##Wang H, Sakurai A, Khamsri B, Uchiyama T, Gu H, Adachi A,et al. Unique characteristics of HIV-1 Vif expression. Microbes Infect 2005;7(3):385-90.##Jia B, Jeon CO. High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives. Open Biol 2016;6(8).##Indriarini D, Rukmana A, Yasmon A. Cloning and expression of MCE1A gene from Mycobacterium tuberculosis Beijing and H37RV strain for vaccine candidate development. Afr J Infect Dis 2018;12(1 Suppl):127-32.##Khatami Hr, Fallah zadeh R, Fallah mehrabadi J, Ghafari MD. Expression assessment of recombinant human granulocyte colony stimulating factor (hG-CSF) in E. coli (Origami / BL21). NCMBJ 2015;5(19):19-23.##Kang CY. Molecular approaches to AIDS vaccine development using baculovirus expression vectors. Methods Mol Biol 1995;39:295-315.##Andrew A, Strebel K. HIV-1 accessory proteins: Vpu and Vif. Methods Mol Biol 2014;1087:135-58.##Müller-Taubenberger A, Anderson K. Recent advances using green and red fluorescent protein variants. Appl Microbiol Biotechnol 2007;77(1):1-12.##

Determining the Specific Activity of Anti-Rabies Sera and Immunoglobulin Using Atomic Force Microscopy of Cell Cultures 2 2 Background: Mouse neutralization test is widely used to determine the level of anti-rabies antibodies, but it is labor-intensive and time consuming. Alternative methods for determining the neutralizing activity of anti-rabies sera and immunoglobulin in cell cultures are also known. Methods such as FAVN and RFFIT involve the use of fluorescent diagnostics. Determination of Cytopathic Effect (CPE) is often complicated due to features of rabies virus replication in cells. Atomic Force Microscopy (AFM) is able to detect the interaction of the virus with the cell at an early stage. Therefore, in this study, a method has been developed for determining the specific activity of anti-rabies sera and immunoglobulin using AFM of cell cultures.  Methods: The method is based on the preliminary interaction of rabies virus with samples of rabies sera or immunoglobulin drug, adding the specified reaction mixture to cell culture (Vero or BHK-21), and then measuring the surface roughness of the cells using AFM. AFM was carried out in the intermittent contact mode by the mismatch method in the semi-contact mode. The results were compared with the values obtained in the mouse neutralization test. The consistency of the results obtained by both methods was evaluated by Bland-Altman method. Results: The increment in the surface roughness of the cells is a consequence of the damaging effect of the virus, which is weakened as a result of its neutralization by rabies antibodies. A dilution allowing 50% suppression of the increase in the surface roughness of cells was selected as the titer of rabies sera or immunoglobulin. In this case, the recommended range for determining the antibody titer is from 1:100 to 1:3000. Conclusion: For the first time, a new methodological approach in virology and pharmaceutical research is presented in this study. The use of the proposed methodological technique will reduce the time from 21 to 2 days to obtain results in comparison with the mouse neutralization test; also, fewer laboratory animals are required in this approach which is in agreement with 3 R Principle. 136 142 Sergey V Generalov Pavel S Erokhin Russian Research Anti-Plague Institute Microbe Russia Oleg S Kuznetsov Russian Research Anti-Plague Institute Microbe Russia Elena G Abramova Russian Research Anti-Plague Institute MicrobeSaratov State Vavilov Agrarian University Saratov State Vavilov Agrarian University RussiaRussia Ivan M Zhulidov Russian Research Anti-Plague Institute Microbe Russia Natalya A Osina Russian Research Anti-Plague Institute Microbe Russia Antibody activityAtomic force microscopyRabies immunoglobulinRabies serumRabies virusRoughness 40466.pdf World Health Organization. (‎2018)‎. WHO expert consultation on rabies: third report. World Health Organization.##World Health Organization, Rupprecht, Charles E, Fooks, Anthony R & Abela-Ridder, Bernadette. (‎2018)‎. Laboratory techniques in rabies, volume 1, 5th ed. World Health Organization.##Salvi NC, Deopurkar RL, Waghmare AB, Khadilkar MV, Kalolikar MY, Gade SK, et al. Validation of indirect ELISA for quantitative testing of rabies antibodies during production of antirabies serum using equines. Procedia in Vaccinology 2010;2(1):3-11.##Korimbocus J, Dehay N, Tordo N, Cano F, Morgeaux S. Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use. Vaccine 2016;34(28):3310-6.##Zhao R, Yu P, Shan Y, Thirumeni N, Li M, Lv Y, et al. Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects. Vaccine 2019;37(41):6060-7.##Bahloul C, Taieb D, Kaabi B, Diouani MF, Ben Hadjahmed S, Chtourou Y, et al. Comparative evaluation of specific ELISA and RFFIT antibody assays in the assessment of dog immunity against rabies. Epidemiol Infect 2005;133(4):749-57.##Welch RJ, Anderson BL, Litwin CM. An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. J Med Microbiol 2009;58(Pt 6):806-10.##Ondrejková A, Süli J, Ondrejka R, Slepecká E, Prokeš M, Čechvala P, et al. Detection of rabies antibodies in dog sera. Pol J Vet Sci 2015;18(1):47-51.##Cliquet F, Aubert M, Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralizing antibody. J Immunol Methods 1998;212(1):79-87.##Human rabies immunoglobulin, monograph 0723. Ph. Eur. 6th Edition. Strasbourg, France: Council of Europe; 2013.##Hemmat SA, Amany MA, Shendy MB, Attyat MK. Estimation of rabies antibodies in animal sera using different techniques. Zag Vet J 2015;43(1):160-6.##Crick J, King A. Culture of Rabies Virus in Vitro. In: Campbell JB, Charlton KM, editors. Rabies. Boston (MA): Kluwer Academic Publishers; 1988.p. 7, 47-66.##Motamedifar M, Noorafshan A. Cytopathic effect of the herpes simplex virus type 1 appears stereologically as early as 4 h after infection of Vero cells. Micron 2008;39(8):1331-4.##Noorafshan A, Motamedifar M, Karbalay-Doust S. Estimation of the cultured cells' volume and surface area: application of stereological methods on vero cells infected by rubella virus. Iran J Med Sci 2016;41(1):37-43.##Kuznetsov YG, McPherson A. Atomic force microscopy in imaging of viruses and virus-infected cells. Microbiol Mol Biol Rev 2011;75(2):268-85.##Ohnesorge FM, Hörber JK, Häberle W, Czerny CP, Smith DP, Binnig G. AFM review study on pox viruses and living cells. Biophys J 1997;73(4):2183-94.##Laskowski D, Strzelecki J, Pawlak K, Dahm H, Balter A. Effect of ampicillin on adhesive properties of bacteria examined by atomic force microscopy. Micron 2018;112:84-90.##Dubrovin EV, Voloshin AG, Kraevsky SV, Ignatyuk TE., Abramchuk SS, Yaminsky IV, et al. Atomic force microscopy investigation of phage infection of bacteria. Langmuir 2008;24(22):13068-74.##Pi J, Li B, Tu L, Zhu H, Jin H, Yang F, et al. Investigation of quercetin-induced HepG2 cell apoptosis-associated cellular biophysical alterations by atomic force microscopy. Scanning 2016;38(2):100 -12.##Tiwari PM. Eroglu E, Buyoglu-Barnum S, He Q, Willing GA, Vig K, et al. Atomic force microscopic investigation of respiratory syncytial virus infection in Hep-2 cells. J Microsc 2014; 253(1):31-41.##Trindade GS, Vilela JM, Ferreira JM, Aguiar PH, Leite JA, Guedes MI, et al. Use of atomic force microscopy as a diagnostic tool to identify orthopoxvirus. J Virol Methods 2007;141(2):198-204.##Coelho-Dos-Reis JG, Gomes OA, Bortolini DE, Martins ML, Almeida MR, Martins CS, et al. Evaluation of the effects of Quercetin and Kaempherol on the surface of MT-2 cells visualized by atomic force microscopy.##J Virol Methods 2011;174(1-2):47-52. https://pubmed.ncbi.nlm.nih.gov/21507333/23. Moloney M, McDonnell L, O’Shea H. Atomic force microscopy analysis of enveloped and non-enveloped viral entry into, end egress from, cultured cells. Ultramicrocopy 2004;100(3-4):163-9.##Lee G, Lee S, Young J, Quan F. Nanostructural characterization of Sf9 cells during virus-like particles generation. Scanning 2016;38(6):735-42.##Reese AR, Xu B. Single-molecule detection of proteins and toxins in food using atomic force microscopy. Trends in Food Science & Technology 2009;83:277-84.##Shebanova AS, Savvateev MN, Maluchenko NV, Trofimov DYu, Agapov II. [A new method for quantitative estimation of the virus particles number]. Biomed Khim 2009;55(5):610-20. Russian.##Savvateev M, Kozlovskaya N, Moisenovich M, Tonevitsky A, Agapov I, Maluchenko N, et al. Atomic force microscopy for investigation of ribosome‐inactivating proteins’ type II tetramerization. AIP Conference Proceedings 2009;696:428-32.##Generalov SV, Erokhin PS, Krasovskaya TYu, Osina NA, Abramova EG, Nikiforov AK, et al. [A study of the ultrastructure of the surface of the transplantable line Vero cells infected with the rabies virus (RABV, Lissavirus, Rhabdoviridae)]. Problems of Virology 2017;62(5): 227-32. Russian.##Abramova EG, Nikiforov AK, Lobovikova OA, Eremin SA, Vasin YuG, Mikheeva TA, et al. [Heterologous anti-rabies immunoglobulin - results of the first five years of production]. Problems of Particularly Dangerous Infections 2010;(3(105):58-62. Russian.##Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1(8476):307-10.##Schutte K, Szczepanska A, Halder M, Cussler K, Sauer UG, Stirling C, et al. Modern science for better quality control of medicinal products “Towards global harmonization of 3Rs in biologicals”: The report of an EPAA workshop. Biologicals 2017;48:55-65.##

Detection of Aneuploidies in Products of Conception and Neonatal Deaths in Iranian Patients Using the Multiplex Ligation-Dependent Probe Amplification (MLPA) 2 2 Background: Around 70% of all pregnancies (Including 15% of clinically-recognized ones) are lost due to various fetal or maternal disorders. Chromosomal aneuploidies are among the most common causes of pregnancy loss. Standard chromosome analysis using G-banding technique (Karyotype) is the technique of choice in studying such abnormalities; however, this technique is time-consuming and  sensitive, and limited by vulnerabilities such as cell culture failure. The use of molecular cytogenetic techniques, including array-based techniques and Multiplex Ligation-Dependent Probe Amplification (MLPA), has been proposed to overcome the limitations of this method to study the products of conception. This study has been designed to investigate the feasibility of using MLPA technique as a standalone genetic testing, with histopathologic examinations and genetic counseling to detect aneuploidies in products of conception and neonatal deaths. Methods: Forty-two verified fetal and neonatal samples were studies and genetic counseling was scheduled for all parents. Histopathologic examinations were carried out on the products of conception, and appropriate fetal tissues were separated for genetic studies. Following DNA extraction and purification, MLPA was carried out to investigate chromosomal aneuploidies. Results: Nine samples (21.42%) were diagnosed to be affected with aneuploidy. Detected aneuploidies were trisomy 22 (n=3), trisomy 21(n=1), trisomy 18 (n=2), trisomy 16 (n=1), trisomy 13 (n=1), and monosomy of chromosome X (n=1). The MLPA analysis results were conclusive for all of the fetal samples (Success rate: 100%). Conclusion: These results suggest that MLPA, as a standalone genetic testing, is an accurate, rapid, and reliable method in overcoming the limitations of standard cytogenetic techniques in genetic investigation of products of conception. 143 148 Sara Khorami Sarvestani Fetal Health Research Center, Hope Generation FoundationReproductive Immunology Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR) IranIran Maryam Rafati Fetal Health Research Center, Hope Generation FoundationReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran IranIran Haleh Soltanghoraee Fetal Health Research Center, Hope Generation Foundation Iran Azadeh Hoseini Fetal Health Research Center, Hope Generation Foundation Iran Azadeh Soltani Avicenna Fertility Center, Avicenna Research Institute, ACECR Iran Koosha Jalilian Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University Iran Saeed Reza Ghaffari AneuploidyConceptionPerinatal deaths 40467.pdf Hyde KJ, Schust DJ. Genetic considerations in recurrent pregnancy loss. Cold Spring Harb Perspect Med 2015;5(3):a023119.##Yang L, Tao T, Zhao X, Tao H, Su J, Shen Y, et al. Association between fetal chromosomal abnormalities and the frequency of spontaneous abortions. Exp Ther Med 2020;19(4):2505-10.##Nussbaum R, McInnes R, Willard H. Thompson & Thompson Genetic in Medicine. 7th ed. Elsiver; 2007. 600 p.##Jia CW, Wang L, Lan YL, Song R, Zhou LY, Yu L, et al. Aneuploidy in early miscarriage and its related factors. Chin Med J (Engl) 2015;128(20):2772-6.##Stephenson MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002;17(2):446-51.##Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril 2000;73(2):300-4.##Karaoguz MY, Nas T, Konac E, Ince D, Pala E, Menevse S. Is cytogenetic diagnosis of 46,XX karyotype spontaneous abortion specimens erroneous? Fluorescence in situ hybridization as a confirmatory technique. J Obstet Gynaecol Res 2005;31(6):508-13.##Bell KA, Van Deerlin PG, Haddad BR, Feinberg RF. Cytogenetic diagnosis of "normal 46,XX" karyotypes in spontaneous abortions frequently may be misleading. Fertil Steril 1999;71(2):334-41.##van den Berg MM, van Maarle MC, van Wely M, Goddijn M. Genetics of early miscarriage. Biochim Biophys Acta 2012;1822(12):1951-9.##Boormans EM, Birnie E, Oepkes D, Galjaard RJ, Schuring-Blom GH, van Lith JM, et al. Comparison of multiplex ligation-dependent probe amplification and karyotyping in prenatal diagnosis. Obstet Gynecol 2010;115(2 Pt 1):297-303.##Diego-Alvarez D, Rodriguez de Alba M, Cardero-Merlo R, Diaz-Recasens J, Ayuso C, Ramos C, et al. MLPA as a screening method of aneuploidy and unbalanced chromosomal rearrangements in spontaneous miscarriages. Prenat Diagn 2007;27(8):765-71.##Smits MAJ, van Maarle M, Hamer G, Mastenbroek S, Goddijn M, van Wely M. Cytogenetic testing of pregnancy loss tissue: a meta-analysis. Reprod Biomed Online 2020;40(6):867-79.##Massalska D, Zimowski JG, Bijok J, Pawelec M, Czubak-Barlik M, Jakiel G, et al. First trimester pregnancy loss: Clinical implications of genetic testing. J Obstet Gynaecol Res 2017;43(1):23-9.##Yan JB, Xu M, Xiong C, Zhou DW, Ren ZR, Huang Y, et al. Rapid screening for chromosomal aneuploidies using array-MLPA. BMC Med Genet 2011;12:68.##Gu Y, Xie JS, Luo FW, Geng Q, Zhang HK, Shen HN, et al. [Karyotype analysis of chorionic villi from pregnant women with missed abortion using multiplex ligation-dependent probe amplification]. Zhonghua Fu Chan Ke Za Zhi 2009;44(7):509-13. Chinese.##Caramins MC, Saville T, Shakeshaft R, Mullan GL, Miller B, Yip MY, et al. A comparison of molecular and cytogenetic techniques for the diagnosis of pregnancy loss. Genet Med 2011;13(1):46-51.##Zimowski JG, Massalska D, Pawelec M, Bijok J, Michalowska A, Roszkowski T. First-trimester spontaneous pregnancy loss-molecular analysis using multiplex ligation-dependent probe amplification. Clin Genet 2016;89(5):620-4.##Carvalho B, Doria S, Ramalho C, Brandao O, Sousa M, Matias A, et al. Aneuploidies detection in miscarriages and fetal deaths using multiplex ligation-dependent probe amplification: an alternative for speeding up results? Eur J Obstet Gynecol Reprod Biol 2010;153(2):151-5.##Omrani MD, Azizi F, Rajabibazl M, Safavi Naini N, Omrani S, Abbasi AM, et al. Can we rely on the multiplex ligation-dependent probe amplification method (MLPA) for prenatal diagnosis? Iran J Reprod Med 2014;12(4):263-8.##Saxena D, Agarwal M, Gupta D, Agrawal S, Das V, Phadke S. Utility and limitations of multiplex ligation-dependent probe amplification technique in the detection of cytogenetic abnormalities in products of conception. J Postgrad Med 2016;62(4):239-41.##McClelland LS, Allen SK, Larkins SA, Hamilton SJ, Marton T, Cox PM, et al. Implementation and experience of an alternative QF-PCR and MLPA diagnostic strategy to detect chromosomal abnormalities in fetal and neonatal pathology samples. Pediatr Dev Pathol 2011;14(6):460-8.##Saadat M, Ansari-Lari M, Farhud D. Short report consanguineous marriage in Iran. Ann Hum Biol 2004;31(2):263-9.##Ernst LM, Gawron L, Fritsch MK. Pathologic examination of fetal and placental tissue obtained by dilation and evacuation. Arch Pathol Lab Med 2013;137(3):326-37.##Stuppia L, Antonucci I, Palka G, Gatta V. Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci 2012;13(3):3245-76.##

An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of miR-21 on T-cell Related Target Genes in Multiple Sclerosis 2 2 Background: Overexpression of miR-21 is a characteristic feature of patients with Multiple Sclerosis (MS) and is involved in gene regulation and the expression enhancement of pro-inflammatory factors including IFNγ and TNF-α following stimulation of T-cells via the T Cell Receptor (TCR). In this study, a novel integrated bioinformatics analysis was used to obtain a better understanding of the involvement of miR-21 in the development of MS, its protein biomarker signatures, RNA levels, and drug interactions through existing microarray and RNA-seq datasets of MS. Methods: In order to obtain data on the Differentially Expressed Genes (DEGs) in patients with MS and normal controls, the GEO2R web tool was used to analyze the Gene Expression Omnibus (GEO) datasets, and then Protein-Protein Interaction (PPI) networks of co-expressed DEGs were designed using STRING. A molecular network of miRNA-genes and drugs based on differentially expressed genes was created for T-cells of MS patients to identify the targets of miR-21, that may act as important regulators and potential biomarkers for early diagnosis, prognosis and, potential therapeutic targets for MS. Results: It found that seven genes (NRIP1, ARNT, KDM7A, S100A10, AK2, TGFβR2, and IL-6R) are regulated by drugs used in MS and miR-21. Finally, three overlapping genes (S100A10, NRIP1, KDM7A) were identified between miRNA-gene-drug network and nineteen genes as hub genes which can reflect the pathophysiology of MS.  Conclusion: Our findings suggest that miR-21 and MS-related drugs can act synergistically to regulate several genes in the existing datasets, and miR-21 inhibitors have the potential to be used in MS treatment. 149 165 Mostafa Manian Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences Iran Ehsan Sohrabi Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences Iran Nahid Eskandari Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences Iran Mohammad-Ali Assarehzadegan Department of Immunology, Faculty of Medicine, Iran University of Medical Sciencesmmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences Department of Immunology, Faculty of Medicine, Iran University of Medical Sciencesmmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences IranIran Gordon A. Ferns Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton BN1 9PH Brighton and Sussex Medical School, Division of Medical Education, Falmer, Brighton BN1 9PH UK Mitra Nourbakhsh Department of Biochemistry and Nutrition, Faculty of Medicine, Iran University of Medical Sciences Department of Biochemistry and Nutrition, Faculty of Medicine, Iran University of Medical Sciences Iran Mir Hadi Jazayeri Department of Immunology, Faculty of Medicine, Iran University of Medical SciencesImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences Department of Immunology, Faculty of Medicine, Iran University of Medical SciencesImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences IranIran Reza Nedaeinia BioinformaticsMicroRNAsMultiple sclerosisT-cell 40468.pdf Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9(7):727-39.##Sadeghian-Rizi T, Alsahebfosoul F, Kazemi M, Khanahmad H, Jahanian-Najafabadi A. Association of AIRE polymorphism and the susceptibility to multiple sclerosis in Iranian population. Avicenna J Med Biotechnol 2018;10(2):110-4.##Munoz-Culla M, Irizar H, Otaegui D. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet 2013;6:63-73.##Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41(7):824-8.##Didonna A, Oksenberg JR. Genetic determinants of risk and progression in multiple sclerosis. Clin Chim Acta 2015;449:16-22.##Kim YA, Wuchty S, Przytycka TM. Identifying causal genes and dysregulated pathways in complex diseases. PLoS Comput Biol 2011;7(3):e1001095.##Malkki H. Blood-based biomarkers provide insight into progressive MS. Nat Rev Neurol 2014;10(11):612.##Raphael I, Webb J, Stuve O, Haskins W, Forsthuber T. Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol 2015;11(1):69-91.##Hosseini SM, Soltani BM, Tavallaei M, Mowla SJ, Tafsiri E, Bagheri A, et al. Clinically significant dysregulation of hsa-miR-30d-5p and hsa-let-7b expression in patients with surgically resected Non-small cell lung cancer. Avicenna J Med Biotechnol 2018;10(2):98-104. ##Soreq H, Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol Med 2011;17(10):548-55.##Hendrickx DAE, van Scheppingen J, van der Poel M, Bossers K, Schuurman KG, van Eden CG, et al. Gene expression profiling of multiple sclerosis pathology identifies early patterns of demyelination surrounding chronic active lesions. Front Immunol 2017;8:1810.##Muñoz-San Martín M, Reverter G, Robles-Cedeño R, Buxò M, Ortega FJ, Gómez I, et al. Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. J Neuroinflammation 2019;16(1):220.##Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97.##Jernås M, Malmeström C, Axelsson M, Nookaew I, Wadenvik H, Lycke J, et al. MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol 2013;14(1):32.##Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell Prolif 2015;48(1):1-6.##D'Ambrosio A, Pontecorvo S, Colasanti T, Zamboni S, Francia A, Margutti P. Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev 2015;14(12):1097-110.##Satoh JI, Tabunoki H, Yamamura T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 2009;15(5):531-41.##Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L. Analysis of microRNA and gene expression profiles in multiple sclerosis: integrating interaction data to uncover regulatory mechanisms. Sci Rep 2016;6:34512.##Srinivasan S, Severa M, Rizzo F, Menon R, Brini E, Mechelli R, et al. Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis. Sci Rep 2017;7(1):8981.##Safari-Alighiarloo N, Rezaei-Tavirani M, Taghizadeh M, Tabatabaei SM, Namaki S. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. PeerJ 2016;4:e2775.##Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, et al. Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: nsights from systems biology analysis. Medicina (Kaunas) 2019;55(1):20.##Islam T, Rahman MR, Karim MR, Huq F, Quinn JMW, Moni MA. Detection of multiple sclerosis using blood and brain cells transcript profiles: Insights from comprehensive bioinformatics approach. Informatics in Medicine Unlocked 2019;16:100201.##Liu Y, Chen G, Liu H, Li Z, Yang Q, Gu X, et al. Integrated bioinformatics analysis of miRNA expression in Ewing sarcoma and potential regulatory effects of miR-21 via targeting ALCAM/CD166. Artificial Cells 2019;47(1):2114-22.##Luo D, Fu J. Identifying characteristic miRNAs-genes and risk pathways of multiple sclerosis based on bioinformatics analysis. Oncotarget 2018;9(4):5287-300.##Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci 2014;11(8):810-8.##Lin Q, Geng Y, Zhao M, Lin S, Zhu Q, Tian Z. MiR-21 regulates TNF-α-induced CD40 expression via the SIRT1-NF-κB pathway in renal inner medullary collecting duct cells. Cell Physiol Biochem 2017;41(1):124-36.##Piket E, Zheleznyakova GY, Kular L, Jagodic M. Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview. J Autoimmun 2019;101:17-25.##Tufekci KU, Oner MG, Genc S, Genc K. MicroRNAs and Multiple Sclerosis. Autoimmune Dis 2011;2011:807426.##Sheedy FJ. Turning 21: Induction of miR-21 as a key switch in the inflammatory response. Front Immunol 2015;6(19).##Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett 2011;504(1):9-12.##Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, et al. Toward the blood-borne miRNome of human diseases. Nat Methods 2011;8(10):841-3.##Hellberg S, Eklund D, Gawel DR, Kopsen M, Zhang H, Nestor CE, et al. Dynamic response genes in CD4+ T cells reveal a network of interactive proteins that classifies disease activity in multiple sclerosis. Cell Rep 2016;16(11):2928-39.##Corvol JC, Pelletier D, Henry RG, Caillier SJ, Wang J, Pappas D, et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 2008;105(33):11839-44.##Jernas M, Malmestrom C, Axelsson M, Nookaew I, Wadenvik H, Lycke J, et al. MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol 2013;14:32.##Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain 2011;134(Pt 2):542-54.##Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commu. 2016;7:12015.##Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res 2017;46(D1):D360-D70.##Mou T, Zhu D, Wei X, Li T, Zheng D, Pu J, et al. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. World J Surg Oncol 2017;15(1):63.##Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, et al. DGIdb: mining the druggable genome. Nat Methods 2013;10(12):1209-10.##Cotto KC, Wagner AH, Feng Y-Y, Kiwala S, Coffman AC, Spies G, et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Res 2017;46(D1):D1068-D73.##Ando Y, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun 2013;41:111-9.##Tufekci KU, Oner MG, Genc S, Genc K. MicroRNAs and multiple sclerosis. Autoimmune Dis 2010;2011:807426.##Kim C, Hu B, Jadhav RR, Jin J, Zhang H, Cavanagh MM, et al. Activation of miR-21-regulated pathways in immune aging selects against signatures characteristic of memory T cells. Cell Rep 2018;25(8):2148-62.e5.##Dos Passos GR, Sato DK, Becker J, Fujihara K. Th17 Cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications. Mediators Inflamm 2016;2016:5314541.##van Langelaar J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, Spilt IM, Siepman TA, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain 2018;141(5):1334-49.##Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 2013;333(1-2):76-87.##Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, et al. Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. J Immunol Res 2014;2014:897249.##Zorlu N, Hoffjan S, Haghikia A, Deyneko IV, Epplen JT. Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis. J Neuroimmunol 2019;334:576979.##Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, Jeon YJ, et al. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 2007;9(11):1303-10.##Lagresle-Peyrou C, Six EM, Picard C, Rieux-Laucat F, Michel V, Ditadi A, et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet 2009;41(1):106-11.##Christopher A, Kaur R, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res 2016;7(2):68-74.##Flaisher-Grinberg S, Tsai HC, Feng X, Wei LN. Emotional regulatory function of receptor interacting protein 140 revealed in the ventromedial hypothalamus. Brain Behav Immun 2014;40:226-34.##He H, Hu Z, Xiao H, Zhou F, Yang B. The tale of histone modifications and its role in multiple sclerosis. Hum Genomics 2018;12(1):31.##Allnoch L, Baumgärtner W, Hansmann F. Impact of astrocyte depletion upon inflammation and demyelination in a murine animal model of multiple sclerosis. Int J Mol Sci 2019;20(16):3922.##Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, et al. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther 2016;23(8):246-53.##Nedaeinia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M, et al. Current status and perspectives regarding LNA-Anti-miR oligonucleotides and microRNA miR-21 inhibitors as a potential therapeutic option in treatment of colorectal cancer. J Cell Biochem 2017;118(12):4129-40.##

Association of a Functional Single Nucleotide Polymorphism (rs874040) in the RBPJ Gene with Susceptibility to Rheumatoid Arthritis in Iranian Population 2 2 Background: Rheumatoid Arthritis (RA) is a progressive, heterogeneous, and common multifactorial autoimmune disease. Several Genome-Wide Association Studies (GWASs) have revealed more than 100 risk loci for RA. One of these loci is a functional single nucleotide polymorphism (rs874040; G>C) near the recombination signal-binding protein for the immunoglobulin kappa J region (RBPJ) gene. RBPJ can convert into a transcriptional activator upon activation of the canonical Notch pathway. Notch signaling has recently emerged as an important regulator of immune responses in inflammation and autoimmune diseases. In the present study, the possible association between SNP rs874040 (G>C) upstream of the RBPJ gene with RA risk was assessed in Iranian population. Methods: A case-control study including 60 RA patients and 44 control subjects was conducted to estimate rs874040 genotypes using real‑time polymerase chain reaction High Resolution Melting (HRM) method. Results: Logistic regression analysis indicated that homozygous CC and heterozygous GC genotypes increase the risk of RA compared with GG genotype (CC vs. GG; OR=11.36; 95% CI [3.93-33.33] and CG vs. GG; OR=3.78; 95% CI [1.30-10. 98]). Besides, subjects with C allele were more frequently affected with RA than subjects with G allele (OR=10.42; 95% CI [5.21-20.83]). Furthermore, in the patient group, a significant correlation was found between C-reactive protein concentrations and rs874040 polymorphism (p<0.05). Conclusion: Our findings propose a substantial correlation between rs874040 polymorphism and RA risk in Iranian population. 166 170 Mansour Salesi Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Science Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Science Iran Mahdieh Oboodiyat Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Science Department of Internal Medicine, Faculty of Medicine, Isfahan University of Medical Science Iran Rasoul Salehi Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences Iran Bahram Pakzad GenotypeGenome-Wide Association StudyIranRheumatoid arthritisSingle nucleotide polymorphisms 40469.pdf Glocker MO, Guthke R, Kekow J, Thiesen HJ. Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine. Med Res Rev 2006;26(1):63-87. ##England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken) 2019;71(12):1540-55. ##Simpson C, Franks C, Morrison C, Lempp H. The patient's journey: rheumatoid arthritis. BMJ 2005;331(7521):887-9. ##Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract 2018;27(6):501-7. ##Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019;78(11):1463-71. ##Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990;16(3):513-37. ##Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11(3):229. ##Jalil SF, Arshad M, Bhatti A, Ahmad J, Akbar F, Ali S, et al. Rheumatoid arthritis: what have we learned about the causing factors? Pak J Pharm Sci 2016;29(2). ##Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 2017;31(1):3-18. ##Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 2013;45(2):170-9. ##MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43(1):30-7. ##Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K. Genetics of rheumatoid arthritis: 2018 status. Ann Rheum Dis 2019;78(4):446-53.##Kim K, Bang SY, Lee HS, Bae SC. Update on the genetic architecture of rheumatoid arthritis. Nat Rev Rheumatol 2017;13(1):13-24. ##Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol 2009;9(2):116-24. ##Shang Y, Smith S, Hu X. Role of Notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell 2016;7(3):159-74. ##Tanigaki K, Honjo T. Regulation of lymphocyte development by Notch signaling. Nat Immunol 2007;8(5):451-6. ##Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA. Notch 1 signaling regulates peripheral T cell activation. Immunity 2004;20(4):407-15. ##Jiao Z, Wang W, Jia R, Li J, You H, Chen L, et al. Accumulation of FoxP3‐expressing CD4+ CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007;36(6):428-33. ##Ma D, Zhu Y, Ji C, Hou M. Targeting the Notch signaling pathway in autoimmune diseases. Expert Opin Ther Targets 2010;14(5):553-65. ##Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH 17 and regulatory T cells. Nature 2006;441(7090):235-8. ##McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo. Nat Immunol 2009;10(3):314-24. ##Orent W, Mchenry AR, Rao DA, White C, Klein HU, Bassil R, et al. Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells. Hum Mol Genet 2016;25(2):404-17. ##Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423(6937):356-61. ##Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010;42(6):508-14. ##Vieceli Dalla Sega F, Fortini F, Aquila G, Campo G, Vaccarezza M, Rizzo P. Notch signaling regulates immune responses in atherosclerosis. Front Immunol 2019;10:1130. ##Radtke F, Fasnacht N, MacDonald HR. Notch signaling in the immune system. Immunity 2010;32(1):14-27. ##Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137(2):216-33. ##zu Horste GM, Wu C, Wang C, Cong L, Pawlak M, Lee Y, et al. RBPJ controls development of pathogenic Th17 cells by regulating IL-23 receptor expression. Cell Reports 2016;16(2):392-404.##Aslam MM, John P, Fan KH, Bhatti A, Aziz W, Ahmed B, et al. Investigating the GWAS-implicated loci for rheumatoid arthritis in the Pakistani population. Disease Markers 2020;2020.##

ZHER2 Affibody as a Good Candidate for Detection of Metastatic Prostate Cancer 2 2 Prostate cancer (PCa) is the second leading cause of cancer death in men. About one in 39 will die of prostate cancer and about one man out of seven is diagnosed with the problem. The expression of the Epidermal Growth Factor Receptor (EGFR) is shown in the progression of androgen independent PCa. EGFR has emerged as a promising therapeutic target for patients with castration‑resistant PCa. There is an urgent need for detection of EGFR expression and monitoring the treatment in prostate cancer. Affibodies are small engineered proteins with a high affinity to a large number of target proteins or peptides. Affibodies are three-helix bundles of 58 amino acids based on Z domain of staphylococcal protein A; ZHER2 is one of them with the high-affinity to Human Epidermal growth factor Receptor 2 (HER2). Positron Emission Tomography (PET) imaging with 18F-Labeled ZHER2: 2891 affibody can be a good candidate for prostate cancer detection. 171 171 Mahboobeh Nazari Ramin Radmanesh Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Iran Prostate cancerPositron Emission Tomography (PET)ZHER2 affibody 40470.pdf Filippou P, Ferguson III JE, Nielsen ME. Epidemiology of prostate and testicular cancer. S Semin Intervent Radiol 2016;33(3):182-5. ##Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001;116(2):234-9. ##Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002;168(4):1412-4. ##Day KC, Hiles GL, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Can Res 2017;77(1):74-85. ##Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166(4):1514-9. ##Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584(12):2670-80. ##Tolmachev V, Orlova A. Affibody molecules as targeting vectors for PET imaging. Cancers (Basel) 2020;12(3):651. ##Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006;66(8):4339-48. ##Sexton K, Tichauer K, Samkoe KS, Gunn J, Hoopes PJ, Pogue BW. Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PloS One 2013;8(4):e60390. ##